Neurology:西诺巴胺辅助治疗可显著改善未控制的癫痫局灶性发作

2021-04-14 MedSci原创 MedSci原创

尽管在过去25年中,新的抗癫痫药物(AEDs)越来越多,但仍有相当一部分(>30%)患者的癫痫发作仍未得到控制。西诺巴胺是一种新型的四唑烷基氨基甲酸酯衍生物,最近在美国被批准用于治疗成人局灶性(

尽管在过去25年中,新的抗癫痫药物(AEDs)越来越多,但仍有相当一部分(>30%)患者的癫痫发作仍未得到控制。西诺巴胺是一种新型的四唑烷基氨基甲酸酯衍生物,最近在美国被批准用于治疗成人局灶性(部分发作)癫痫发作。近日,一项多中心、双盲、安慰剂对照研究评估了辅助西诺巴胺200 mg/d对经1~3种抗癫痫药物治疗后仍未控制的局灶性(部分发作)癫痫患者的疗效和安全性,研究结果已发表于Neurology。

研究纳入18~65岁的局灶性癫痫发作的成年患者,在8周基线期后1:1随机分组(西诺巴胺:安慰剂)。12周的双盲治疗期包括6周的滴定阶段和6周的维持阶段。主要结果是双盲治疗期间每28天癫痫发作频率的百分比变化。

 

220名患者被随机化;113名患者接受西诺巴胺,109名患者接受安慰剂;分别有90.3%和90.8%的患者完成双盲治疗。中位基线发作频率为6.5次/28天(范围0-237)。

 

与安慰剂相比,西诺巴胺治疗组癫痫发作的中位百分比减少(55.6% vs 21.5%;p <0.0001)。西诺巴胺的反应者率(癫痫发作频率减少≥50%)为50.4%,安慰剂为22.2%(p <0.0001)。与安慰剂相比,西诺巴胺可显著减少有运动成分的局灶性发作、意识障碍、局灶性至双侧强直-阵挛性发作。维持期间,28.3%的西诺巴胺治疗和8.8%的安慰剂治疗患者无癫痫发作。任何一组(西诺巴胺vs安慰剂)报告的治疗突发不良事件均大于10%,分别为嗜睡(22.1% vs 11.9%)、头晕(22.1% vs 16.5%)、头痛(12.4% vs 12.8%)、恶心(11.5% vs 4.6%)和疲劳(10.6% vs 6.4%)。

综上所述,该研究结果表明,西诺巴胺200 mg/d辅助治疗可显著改善未控制的癫痫局灶性发作,且耐受性良好。

 

原始出处:

 

Steve S Chung, et al., Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020 Jun 2;94(22):e2311-e2322. doi: 10.1212/WNL.0000000000009530.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2001300, encodeId=6c8620013009a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jul 30 13:14:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009702, encodeId=d2672009e0219, content=<a href='/topic/show?id=c7804e581bc' target=_blank style='color:#2F92EE;'>#局灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47581, encryptionId=c7804e581bc, topicName=局灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed May 19 21:14:05 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956964, encodeId=dee69569642a, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Wed Apr 14 17:16:20 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957114, encodeId=047a95e11448, content=希望有助临床治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Wed Apr 14 23:24:58 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
    2021-07-30 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2001300, encodeId=6c8620013009a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jul 30 13:14:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009702, encodeId=d2672009e0219, content=<a href='/topic/show?id=c7804e581bc' target=_blank style='color:#2F92EE;'>#局灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47581, encryptionId=c7804e581bc, topicName=局灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed May 19 21:14:05 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956964, encodeId=dee69569642a, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Wed Apr 14 17:16:20 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957114, encodeId=047a95e11448, content=希望有助临床治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Wed Apr 14 23:24:58 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2001300, encodeId=6c8620013009a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jul 30 13:14:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009702, encodeId=d2672009e0219, content=<a href='/topic/show?id=c7804e581bc' target=_blank style='color:#2F92EE;'>#局灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47581, encryptionId=c7804e581bc, topicName=局灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed May 19 21:14:05 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956964, encodeId=dee69569642a, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Wed Apr 14 17:16:20 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957114, encodeId=047a95e11448, content=希望有助临床治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Wed Apr 14 23:24:58 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
    2021-04-14 七安

    三人行,必有我师。 #梅斯医学科研互助群# 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2001300, encodeId=6c8620013009a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Jul 30 13:14:05 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009702, encodeId=d2672009e0219, content=<a href='/topic/show?id=c7804e581bc' target=_blank style='color:#2F92EE;'>#局灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47581, encryptionId=c7804e581bc, topicName=局灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed May 19 21:14:05 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956964, encodeId=dee69569642a, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Wed Apr 14 17:16:20 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957114, encodeId=047a95e11448, content=希望有助临床治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Wed Apr 14 23:24:58 CST 2021, time=2021-04-14, status=1, ipAttribution=)]
    2021-04-14 言西早

    希望有助临床治疗。

    0

相关资讯

Lancet Neurology:成人局灶性癫痫发作风险预测: 一项发展和验证研究

癫痫是大脑神经元突发性异常放电,导致短暂的大脑功能障碍的一种慢性疾病。尽管癫痫发作时是短暂的,但其需要长期治疗,并有可能导致严重残疾。

500多万癫痫儿童用药有了新选择,优时比维派特®口服溶液获批上市

2021年3月28日,全球性生物医药企业优时比今天宣布抗癫痫创新药物维派特®(拉考沙胺)口服溶液正式在中国上市。维派特®(拉考沙胺)口服溶液在中国获批用于4岁及以上癫痫患者部分性发作的联合治疗,有望为

Lancet:左乙拉西坦 vs 丙戊酸钠一线治疗特发性全面性或难分类癫痫

对于新确诊的特发性全面性或难分类癫痫患者,左乙拉西坦在治疗效果及成本效益方面均劣于丙戊酸钠

Neurology:炎症相关的血浆蛋白可反映癫痫发作

炎症相关的血浆蛋白可反映癫痫发作

利必通--闲聊云诊室,欢迎您加入!

利必通--闲聊云诊室,欢迎您加入!